Markets
Tech
Media
Success
Video
Markets
Premarkets
Dow
After-Hours
Market Movers
Fear & Greed
World Markets
Investing
Markets Now
Before the Bell
Leading Indicator
Global Energy Challenge
Economy
Tracking America's Recovery
Energy
Tech
Innovate
Gadget
Mission: Ahead
Upstarts
Business Evolved
Work Transformed
Innovative Cities
Unhackable
Media
Reliable Sources
Success
Boss Files
Fresh Money
Cars
Homes
Biz + Leisure
Center Piece
Perspectives
Video
International
Switzerland
India
Davos
Passion to Portfolio
On: Germany
More
Newsletters
About Us
Accessibility and CC
U.S.
World
Politics
Business
Opinion
Health
Entertainment
Tech
Style
Travel
Sports
Video
Shop
VR
More...
Follow CNN Business
Do Not Sell
Pfizer Inc
(NYSE:PFE)
36.54
Delayed Data
As of Jan 22
+0.06
/
+0.16%
Today’s Change
26.43
Today
|||
52-Week Range
43.08
-0.73%
Year-to-Date
Quote
Profile
News
Charts
Forecasts
Financials
Shareholders
Competitors
Latest PFE News
|
Press Releases
Why Pfizer's Future Looks Better in 2021
2:30pm / MotleyFool.com - Paid Partner Content
Is Johnson & Johnson a Buy?
Jan 21 / MotleyFool.com - Paid Partner Content
3 Reasons This Hot Stock May Not Survive 2021
10:30am / MotleyFool.com - Paid Partner Content
3 Reasons to Buy Novavax Stock, and 1 Reason to Sell
Jan 21 / MotleyFool.com - Paid Partner Content
3 Blockbuster Drug Launches to Watch This Year
8:53am / MotleyFool.com - Paid Partner Content
Better Coronavirus Stock: Novavax or Vaxart?
Jan 21 / MotleyFool.com - Paid Partner Content
BioNTech's Potential Winners Beyond Its COVID Vaccine
8:15am / MotleyFool.com - Paid Partner Content
3 COVID Stocks to Buy if You're Not a Big Risk-Taker
Jan 21 / MotleyFool.com - Paid Partner Content
What Kind of Deals Is Pfizer Planning for the Next Few Years?
6:10am / MotleyFool.com - Paid Partner Content
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
Jan 20 / Zacks.com - Paid Partner Content
How Are COVID Vaccine Rollouts Going in Europe?
Jan 23 / MotleyFool.com - Paid Partner Content
Pfizer and BioNTech Report Evidence That Their Vaccine Is Effective Against COVID-19 Variant
Jan 20 / MotleyFool.com - Paid Partner Content
What Does 2021 Hold for BioNTech Stock?
Jan 23 / MotleyFool.com - Paid Partner Content
US Indexes Close Higher Wednesday
Jan 20 / GuruFocus News - Paid Partner Content
Here Are the Biggest Hurdles for COVID Vaccinations
Jan 23 / MotleyFool.com - Paid Partner Content
Moderna Investigating Reports of Allergic Reactions to Its Coronavirus Vaccine
Jan 20 / MotleyFool.com - Paid Partner Content
Could Moderna Be a Millionaire-Maker Stock?
Jan 23 / MotleyFool.com - Paid Partner Content
Gritstone (GRTS) to Begin Coronavirus Vaccine Study, Stock Up
Jan 20 / Zacks.com - Paid Partner Content
Is This Under-the-Radar COVID Stock the Next Moderna?
Jan 23 / MotleyFool.com - Paid Partner Content
My Best SaaS Stock for 2021
Jan 20 / MotleyFool.com - Paid Partner Content
Better Buy: Gilead Sciences vs. Pfizer
Jan 23 / MotleyFool.com - Paid Partner Content
Is It Too Late for Oil Stocks?
Jan 20 / MotleyFool.com - Paid Partner Content
Top Coronavirus Vaccine Makers Will Earn Up to $23 Billion in Revenue This Year, Says New Analysis
Jan 22 / MotleyFool.com - Paid Partner Content
Is Inovio Pharmaceuticals a Buy?
Jan 20 / MotleyFool.com - Paid Partner Content
VBI Vaccines (VBIV) Provides Updates on COVID-19 Vaccine
Jan 22 / Zacks.com - Paid Partner Content
2 High-Yield Dividend Stocks to Buy Now
Jan 20 / MotleyFool.com - Paid Partner Content
Q4 Earnings Season Scorecard and Analyst Reports for Amazon, JPMorgan & Pfizer
Jan 22 / Zacks.com - Paid Partner Content
Biohaven (BHVN) Falls as Troriluzole Fails in Alzheimer's Study
Jan 19 / Zacks.com - Paid Partner Content
What Investors Need to Know About Coronavirus Variants
Jan 22 / MotleyFool.com - Paid Partner Content
Stock Market News for Jan 19, 2021
Jan 19 / Zacks.com - Paid Partner Content
Moderna's (MRNA) Coronavirus Vaccine Study Begins in Japan
Jan 22 / Zacks.com - Paid Partner Content
Grifols (GRFS) to Begin Study on Plasma-Derived COVID-19 Drug
Jan 19 / Zacks.com - Paid Partner Content
More COVID Vaccines Should Become Available With This Major Strategy Change
Jan 22 / MotleyFool.com - Paid Partner Content
Where Will Pfizer Be in 5 Years?
Jan 19 / MotleyFool.com - Paid Partner Content
Bill Ackman Pushes 3 Retailers to Get Directly Involved in U.S. Coronavirus Vaccine Drive
Jan 22 / MotleyFool.com - Paid Partner Content
Wall Street Couldn't Stop Buying Shares of These 2 Stocks in 2020
Jan 19 / MotleyFool.com - Paid Partner Content
3 Cheap Dividend Aristocrats to Buy Right Now
Jan 22 / MotleyFool.com - Paid Partner Content
Stock Market News for Jan 18, 2021
Jan 18 / Zacks.com - Paid Partner Content
3 Warren Buffett Stocks That Should Be Surefire Winners in 2021
Jan 22 / MotleyFool.com - Paid Partner Content
Dr. Reddy's (RDY) to Begin Phase III Study on Sputnik Vaccine
Jan 18 / Zacks.com - Paid Partner Content
Pfizer and BioNTech to Supply WHO's COVID-19 Vaccine Program
Jan 21 / MotleyFool.com - Paid Partner Content
Should You Buy Johnson & Johnson For Its COVID Vaccine?
Jan 18 / MotleyFool.com - Paid Partner Content
United Airlines Suffering Losses Through the 4th Quarter
Jan 21 / GuruFocus News - Paid Partner Content
AstraZeneca (AZN) Gets EU Nod for Improved Imfinzi Dosing
Jan 18 / Zacks.com - Paid Partner Content
Gilead (GILD) Up 19% in the Past Month: What Lies Ahead?
Jan 21 / Zacks.com - Paid Partner Content
The Biggest Drug Competition in 2021 (Hint: It Isn't COVID Vaccines)
Jan 17 / MotleyFool.com - Paid Partner Content
Will Sarepta's (SRPT) Overdependence on Exondys 51 Hurt?
Jan 21 / Zacks.com - Paid Partner Content
This Is the Best News Yet for Moderna's COVID Vaccine
Jan 17 / MotleyFool.com - Paid Partner Content
Should You Get A Vaccine If You've Already Recovered From COVID?
Jan 21 / MotleyFool.com - Paid Partner Content
3 Popular Robinhood Stocks That Should Make You Richer in 2021
Jan 17 / MotleyFool.com - Paid Partner Content